Geneva, Switzerland-based biotech Amal Therapeutics has entered into a collaborative agreement with German family-owned pharma major Boehringer Ingelheim.
Amal will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128, with Boehringer’s anti-PD1 compound, BI754091, in microsatellite stable (MSS) patients with stage IV colorectal cancer. The KISIMA-01 study will begin in the second half of 2019.
Amal’s lead candidate, ATP128, is a chimeric recombinant protein designed using Amal’s proprietary vaccine technology platform, KISIMA. ATP128 comprises of a cell penetrating peptide (CPP) for antigen delivery, a TLR peptide agonist for self-adjuvanticity and a multiple antigenic domain (Mad). ATP128 is designed to treat colorectal cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze